Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

Rekombinanter PDCD1 (Nivolumab Biosimilar) Antikörper (AA 1-167)

Reaktivität: Human FACS, BR, IHC, SPR Wirt: Maus Chimeric 5C4-B8 unconjugated Recombinant Antibody
Produktnummer ABIN7543070
  • Target Alle PDCD1 (Nivolumab Biosimilar) Produkte
    PDCD1 (Nivolumab Biosimilar)
    Antikörpertyp
    Recombinant Antibody
    Bindungsspezifität
    AA 1-167
    Reaktivität
    Human
    Wirt
    • 1
    • 1
    • 1
    Maus
    Klonalität
    • 2
    • 1
    Chimeric
    Konjugat
    • 3
    Dieser PDCD1 (Nivolumab Biosimilar) Antikörper ist unkonjugiert
    Applikation
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    Flow Cytometry (FACS), Blocking Reagent (BR), Immunohistochemistry (IHC), Surface Plasmon Resonance (SPR)
    Verwendungszweck
    Anti-PD-1 [5C4.B8 (Nivolumab)], Mouse IgG1, kappa
    Spezifität
    Nivolumab binds to the extracellular portion of human PD-1 (2.6 nM - Scatchard analysis and SPR) - the antibody also binds to cynomolgus PD-1 with a similar affinity (3.9 nM - SPR). The antibody does not bind to other immunoglobulin superfamily proteins such as CD28, CTLA-4, ICOS and BTLA. The epitope of Nivolumab for both human and cynomolgus PD-1 includes the sequences SFVLNWYR-MSPSNQTDKLAAFPEDR (aa 29-53) and SGTYLCGAISLAPKAQIKE (aa 85-103), as shown by mass spectrometry of protease-treated fragments of PD-1 - these residues are thought to additionally be important for liand binding to PD-1. PD-1 is an inhibitory receptor expressed on the surface of T cells. It is able to bind to its ligands PDL-1 and PDL-2 which results in an inhibitory signal leading to decreased T cell proliferation, cytokine protuction and cytotoxic activtiy. PDL-1 is often expressed in human tumors such as melanoma, lung and kidney where it is able to overactivate PD-1 and plays a role in the evasion of cancer cells from the immune system.
    Kreuzreaktivität
    Cynomolgus
    Produktmerkmale

    Original Species of Ab: Human

    Original Format of Ab: IgG4

    Aufreinigung
    Protein A affinity purified
    Immunogen
    mAb PD1.5 was prepared by immunizing IgH and IgK knock-out transgenic mice possessing a human immunoglobulin (heavy chain) minilocus with recombinant human PD-1-Fc protein consisting of the extracellular domain of PD-1 (amino acids 1-167) and the Fc portion of human IgG1, and Chinese hamster ovary (CHO) cells expressing human PD-1. Nivolumab was generated by grafting the variable regions of PD1.5 onto human kappa and IgG4 constant regions containing an S228P mutation (prevents Fab arm exchange with endogenous IgG4 antibodies).
    Klon
    5C4-B8
    Isotyp
    IgG1 kappa
  • Applikationshinweise
    Nivolumab has been shown to bind to PD-1-expressing CHO cells (EC50 ~1.66nM). Nivolumab binds CD4+ T cells (EC50 ~0.64 nM) and stains only memory and effector, and not naiive CD4+ or CD8+ T cells from human peripheral blood by FC. The antibody is able to block the interaction between PD-1 and its ligands PDL-1 and PDL-2 (IC50 ~2.52 nM and ~2.59 nM, respectively - determined by SPR) - these IC50 values are also similar to that measured by FACS to evaluate ligand binding to PD-1 expressed on CHO cells. In an allogenic T-cell/DC MLR, Nivolumab-mediated inhibition of PD-1 results in enhancement of IFNγ release, and also enhances IL-2 secretion (97-139 % over an isotype control) in response to the superantigen SEB using human peripheral blood mononuclear cells. The same is also observed in a CMV-restimulation assay. Nivolumab at very low concentrations (~1.5 ng/mL) is able to enhance T-cell reactivity in the presence of a T-cell receptor stimulus - nivolumab has no stimulatory effect in the absence of antigen or T-cell receptor stimulus. In the therapeutically used human IgG4 (S228P) format, this antibody is unable to mediate ADCC (antibody-dependent cell-mediated cytotoxicity) or CDC (complement-dependent cytotoxicity).
    Kommentare

    This chimeric mouse antibody was made using the variable domain sequences of the original human IgG4 (S228P) format, for improved compatibility with existing reagents, assays and techniques. NOT FOR THERAPEUTIC USE- This is a research-grade biosimilar. This is a chimeric antibody created for improved compatibility with existing reagents, assays and techniques.

    Beschränkungen
    Nur für Forschungszwecke einsetzbar
  • Konzentration
    1 mg/mL
    Buffer
    PBS with 0.02 % Proclin 300.
    Konservierungsmittel
    ProClin
    Vorsichtsmaßnahmen
    This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Lagerung
    4 °C,-20 °C
    Informationen zur Lagerung
    Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.
  • Target
    PDCD1 (Nivolumab Biosimilar)
    Abstract
    PDCD1 (Nivolumab Biosimilar) Produkte
    Substanzklasse
    Biosimilar
    Hintergrund
    CD279, programmed death-1, programmed death 1 , PD1, PD 1, Programmed cell death protein 1, hPD-1, hPD1, hPD 1, BMS-936558, MDX-1106,ONO-4538
    UniProt
    Q15116
Sie sind hier:
Kundenservice